Efthymios Deliargyris
Directeur Technique/Scientifique/R&D chez CYTOSORBENTS CORPORATION
Fortune : 368 490 $ au 31/05/2024
Postes actifs de Efthymios Deliargyris
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CYTOSORBENTS CORPORATION | Directeur Technique/Scientifique/R&D | 01/05/2020 | - |
Historique de carrière de Efthymios Deliargyris
Anciens postes connus de Efthymios Deliargyris
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PLX PHARMA WINDDOWN CORP. | Directeur Technique/Scientifique/R&D | 01/08/2018 | 30/04/2020 |
| ATHENS MEDICAL C.S.A. | Corporate Officer/Principal | 01/01/2004 | 01/01/2010 |
| Wake Forest University | Corporate Officer/Principal | 01/01/2001 | 01/01/2004 |
Formation de Efthymios Deliargyris
| National & Kapodistrian University of Athens | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Grèce | 3 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
| Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ATHENS MEDICAL C.S.A. | Health Services |
| CYTOSORBENTS CORPORATION | Health Technology |
| Entreprise privées | 1 |
|---|---|
PLx Pharma, Inc.
 PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |
- Bourse
- Insiders
- Efthymios Deliargyris
- Expérience
